Biomarkers to predict disease progression and therapeutic response in isolated methylmalonic acidemia
Open Access
- 6 June 2023
- journal article
- review article
- Published by Wiley in Journal of Inherited Metabolic Disease
- Vol. 46 (4) , 554-572
Abstract
Methylmalonic Acidemia (MMA) is a heterogenous group of inborn errors of metabolism caused by a defect in the methylmalonyl‐CoA mutase (MMUT) enzyme or the synthesis and transport of its cofactor, 5′‐deoxy‐adenosylcobalamin. It is characterized by life‐threatening episodes of ketoacidosis, chronic kidney disease, and other multiorgan complications. Liver transplantation can improve patient stability and survival and thus provides clinical and biochemical benchmarks for the development of hepatocyte‐targeted genomic therapies. Data are presented from a US natural history protocol that evaluated subjects with different types of MMA including mut‐type (N = 91), cblB‐type (15), and cblA‐type MMA (17), as well as from an Italian cohort of mut‐type (N = 19) and cblB‐type MMA (N = 2) subjects, including data before and after organ transplantation in both cohorts. Canonical metabolic markers, such as serum methylmalonic acid and propionylcarnitine, are variable and affected by dietary intake and renal function. We have therefore explored the use of the 1‐13C‐propionate oxidation breath test (POBT) to measure metabolic capacity and the changes in circulating proteins to assess mitochondrial dysfunction (fibroblast growth factor 21 [FGF21] and growth differentiation factor 15 [GDF15]) and kidney injury (lipocalin‐2 [LCN2]). Biomarker concentrations are higher in patients with the severe mut0‐type and cblB‐type MMA, correlate with a decreased POBT, and show a significant response postliver transplant. Additional circulating and imaging markers to assess disease burden are necessary to monitor disease progression. A combination of biomarkers reflecting disease severity and multisystem involvement will be needed to help stratify patients for clinical trials and assess the efficacy of new therapies for MMA.Keywords
Funding Information
- National Human Genome Research Institute (1ZIAHG200318‐16)
- Ministero della Salute
This publication has 129 references indexed in Scilit:
- Targeting proximal tubule mitochondrial dysfunction attenuates the renal disease of methylmalonic acidemiaProceedings of the National Academy of Sciences, 2013
- Improved equations estimating GFR in children with chronic kidney disease using an immunonephelometric determination of cystatin CKidney International, 2012
- Neurocognitive Phenotype of Isolated Methylmalonic AcidemiaPediatrics, 2012
- Variable dietary management of methylmalonic acidemia: metabolic and energetic correlationsThe American Journal of Clinical Nutrition, 2011
- Long-term Rescue of a Lethal Murine Model of Methylmalonic Acidemia Using Adeno associated Viral Gene TherapyMolecular Therapy, 2010
- New Equations to Estimate GFR in Children with CKDJournal of the American Society of Nephrology, 2009
- Mitochondrial dysfunction in mut methylmalonic acidemiaThe FASEB Journal, 2008
- Metabolic phenotype of methylmalonic acidemia in mice and humans: the role of skeletal muscleBMC Medical Genetics, 2007
- Effect of growth hormone treatment on serum creatinine concentration in patients with cystinosis and chronic renal diseaseThe Journal of Pediatrics, 1992
- Substrate disposal in metabolic disease: A comparison between rates of in vivo propionate oxidation and urinary metabolite excretion in children with methylmalonic acidemiaThe Journal of Pediatrics, 1989